Thais Lima

Dr. Thais Lima


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in Life Sciences
Verified
Journal Article
Closed access
MCMaria Fernanda Cury-Boaventura
Maria Fernanda Cury-Boaventura
RGRenata Gorjao
Renata Gorjao
TLThais Lima
Thais Lima
Philip NewsholmePhilip Newsholme
Philip Newsholme
RCRui Curi
Rui Curi

1 March 2006 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
MCMaria Fernanda Cury-Boaventura
Maria Fernanda Cury-Boaventura
RGRenata Gorjao
Renata Gorjao
TLThais Lima
Thais Lima
TPTatiane Maria Piva
Tatiane Maria Piva
CPCarmem Maldonado Peres
Carmem Maldonado Peres
RCRui Curi
Rui Curi

1 March 2004 in Toxicology Letters
Verified
Journal Article
Closed access
MMMariza Pires de Melo
Mariza Pires de Melo
TLThais Lima
Thais Lima
TPTania Cristina Pithon-Curi
Tania Cristina Pithon-Curi
RCRui Curi
Rui Curi

1 June 2005 in Toxicology in Vitro
Verified
Journal Article
Closed access
LALuciana Andrade
Luciana Andrade
TLThais Lima
Thais Lima
RCRui Curi
Rui Curi
ACAna Maria Lauro Castrucci
Ana Maria Lauro Castrucci

13 June 2007 in Clinical Science
Verified
Journal Article
Closed access
PDF file
TLThais Lima
Thais Lima
RGRenata Gorjao
Renata Gorjao
EHElaine Hatanaka
Elaine Hatanaka
MCMaria Fernanda Cury-Boaventura
Maria Fernanda Cury-Boaventura
ESErica Paula Portioli Silva
Erica Paula Portioli Silva
RCRui Curi
Rui Curi
Fatty acids (FAs) have been shown to alter leucocyte function and thus to modulate inflammatory and immune responses. In this review, the effects of FAs on several aspects of lymphocyte, neutrophil and macrophage function are discussed. The mechanisms by which FAs modulate the production of lipid mediators, activity of intracellular signalling pathways, activity of lipid-raft-associated proteins, binding to TLRs (Toll-like receptors), control of gene expression, activation of transcription factors, induction of cell death and production of reactive oxygen and nitrogen species are described in this review. The rationale for the use of specific FAs to treat patients with impaired immune function is explained. Substantial improvement in the therapeutic usage of FAs or FA derivatives may be possible based on an improvement in the understanding of the precise molecular mechanisms of action with respect to the different leucocyte types and outcome with respect to the inflammatory responses.

1 September 2004 in Lipids
Verified
Journal Article
Closed access
PDF file
RVRozangela Verlengia
Rozangela Verlengia
RGRenata Gorjao
Renata Gorjao
CKCarla Cristine Kanunfre
Carla Cristine Kanunfre
SBSilvana Bordin
Silvana Bordin
TLThais Lima
Thais Lima
RCRui Curi
Rui Curi